About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
O
Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Disease, Pregnancy (Nurses)
By
12th ESO-EONS Masterclass in Oncology Nursing
FEATURING
Olivia Pagani
August 14, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
17:04
Novartis Oncology
Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…
Feat.
G. Hortobagyi
Featured Video
13:03
Novartis Oncology
CDK4/6 Inhibitor Option for HR+/HER2- mBC: Are All CDK4/6 Inhibitors…
Feat.
D. Slamon
Related Content
AUTOPLAY
ON
11:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …
Feat.
P. Tarantino
17:39
Yale School of Medicine
2023 Menopause Update
Feat.
M. Minkin
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
04:28
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "ASCENT-05/OptimICE-RD (AFT-65): Adjuvant …
Feat.
S. Tolaney
18:08
Novartis Oncology
Expert Discussion: What Is a Key Driver of HR+/HER2- mBC?
Feat.
D. Juric
24:36
ESMO 2022 Conference Coverage
ESMO 2022 Breast Cancer Panel Discussion: Practice-Changing Updates
Feat.
H. Rugo,
J. O'Shaughnessy
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
23:58
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
50:59
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
07:50
Oncology Data Advisor
ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…
Feat.
K. Kalinsky
30:46
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
53:42
PleXus Communications
Managing Woman's Health in Menopause: Evolving Approaches for t…
Feat.
J. Simon,
T. Iyer,
A. Fiffick,
M. Minkin
18:15
Novartis Oncology
CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…
Feat.
G. Hortobagyi
18:49
Yale School of Medicine
Menopause and Hot Flashes: What Medications are Available?
Feat.
M. Minkin
20:42
Total Health
2022 Updates in TNBC
Feat.
I. Schlam
29:44
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Optimal Duration of Endocrine Therapy for Breast Cancer
Feat.
V. Kaklamani
03:05
ecancer
ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…
Feat.
D. Slamon
08:38
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Utility of Ki67 in Guiding Adjuvant Abema…
Feat.
R. Patel
20:16
University of Colorado Cancer Center
Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…
Feat.
V. Borges
